My watch list
my.bionity.com  
Login  

Merck announces the winners of its Advance Biotech Grant program

Merck Awards Grants to Biotechs Focused on Traumatic Brain Injury, Vaccine Development and Chronic Pain

31-May-2019

Merck announced the winners of its Advance Biotech Grant program in North America during its Biotech Start-up Summit at the Cambridge Innovation Center (Massachusetts, U.S.). The grant is given to small- and mid-size biotechnology companies that need funding and expertise to get their therapies to market.

“With more than 60 percent of drugs in the pipeline today being developed by biotechs, we are committed to supporting these start-ups in developing groundbreaking therapeutics,” said Udit Batra, member of the Merck Executive Board and CEO, Life Science. “Our global grant program provides free access to our process development expertise, products and services to help accelerate molecule-to-market efforts.”

The three grant recipients are:

  • RAFT Pharmaceuticals (San Diego, California, U.S.), for its approach to treat chronic pain using a biologic to selectively inhibit neuroinflammation without affecting normal motor or sensory function.
  • Rubicon Biotechnology (Anaheim, California, U.S.), for developing a therapeutic protein, Fv-Hsp72, designed to protect and salvage cells damaged from an acute event, such as traumatic brain injury.
  • TechnoVax Inc (Elmsford, New York, U.S.), for developing a virus-like particle platform that facilitates the development and production of a range of vaccines targeting the prevention of respiratory diseases, hemorrhagic fevers, immunodeficiency and cancers.

Applicants from biotech companies across U.S. and Canada were asked to describe their projects, the medical needs they solve and process development challenges they face to be considered for the grant. In support of the growing biotech ecosystem, grant recipients receive between $40,000 and $100,000 in Merck products and process development support.

Merck selected the winning submissions based on the scientific and societal merit of therapy in development and process challenges and expertise gaps. The program is part of the company’s global biotech commitment to help bring therapies to market, leveraging decades of process development expertise products, and support at any production scale. Additionally, Merck’s BioReliance® End-to-End Services can address key challenges for biotech companies at all stages of molecule development and commercialization in any geography.

Facts, background information, dossiers
  • Advance Biotech Grant
  • grants
More about Merck
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE